Is HRT safe now? What the FDA actually changed
In November 2025 the FDA removed the boxed warnings from hormone therapy labelling. Here is precisely what changed, what did not, and what it means for a decision you are making today.
On 10–11 November 2025 the FDA removed the broad boxed warnings about cardiovascular disease, breast cancer and dementia from hormone therapy labelling. The endometrial-cancer warning on oestrogen-alone products remains. This reflects a reinterpretation of how the 2002 findings were applied, not a finding that hormone therapy is right for everyone.
What to hold on to
- The change is real and it is significant. Most information published before November 2025 describes the old labelling.
- The endometrial-cancer warning on oestrogen-alone products was not removed.
- Timing matters: the risk-benefit picture differs substantially for a woman starting near the transition versus one starting many years after it.
- Route matters: transdermal and oral oestrogen carry different clot and stroke risk profiles, and this is rarely explained clearly.
- None of this makes it a decision to take from a website. It makes it a better-informed conversation to have with a clinician.
What the warnings were, and why they were there
In 2002 the Women’s Health Initiative reported findings that were widely communicated as showing hormone therapy increased the risk of breast cancer, heart disease and stroke. Prescribing collapsed almost overnight, in the United States and internationally, and boxed warnings were added to the labelling.
The subsequent two decades produced a more complicated picture. The trial population was older than the women who typically start hormone therapy, average age 63, many more than a decade past their final period.
The formulation studied was a specific oral combination that is no longer the most commonly prescribed. And the absolute risks, as distinct from the relative risks that made the headlines, were smaller than most women understood.
What changed in November 2025
The FDA removed the broad boxed warnings covering cardiovascular disease, breast cancer and dementia from systemic and vaginal oestrogen products. Officials cited re-analysis indicating substantial benefits when therapy is initiated close to the menopausal transition.
The endometrial-cancer warning on oestrogen-alone products remains, and that is not a technicality. Oestrogen without progesterone, in a woman who still has a uterus, increases endometrial cancer risk. This is why combination therapy exists.
What this does and does not mean for you
It does not mean hormone therapy is now recommended for everyone. It does not erase individual contraindications, a personal history of breast cancer, unexplained vaginal bleeding, active liver disease, or a history of blood clots all still matter, and some of them still rule it out.
What it does mean is that a great deal of the information you will find online, including on major health sites that have not updated their evergreen pages, describes a labelling position that no longer exists.
The two things that are rarely explained well
Timing. The risk-benefit balance is materially different for a woman starting in her late forties or early fifties, close to her final period, than for a woman starting in her mid-sixties. Much of the confusion in public discussion comes from treating those as the same question.
Route. Oestrogen taken by mouth passes through the liver first and affects clotting factors. Oestrogen delivered through the skin, as a patch, gel or spray, largely does not. The difference in venous thromboembolism and stroke risk between the two routes is one of the most clinically useful facts in this whole area and one of the least widely known.
What to do with this
Read it, then take it to someone who can examine you and knows your history. We have a one-page guide of the questions worth asking, built from what women told us their appointments were missing, it is free and there is nothing to buy in it.
Sources
Updated 27 August 2026
The questions to ask your doctor
A one-page guide built from what women told us their appointments were missing. Free, and we will not sell you anything in it.
One email to deliver it, then a weekly note you can leave whenever you like. We never sell your address, and we never attach it to anything you type into the check or the assistant.